A study published in JNCCN—Journal of the National Comprehensive Cancer Network demonstrated that among all patients with neuroendocrine tumors, the risk of dying of cancer was higher than that of dying of other causes—but mortality varies by primary tumor site.
How’s this for a paradox: The better cancer centers become at keeping patients alive, the more expensive cancer care becomes. This brutal tradeoff hits harder in rural areas, where the cancer burden is higher and the investigator and clinical trial representation is lower.
